Skip to main content
OpenTrials
Completed

NCT Number: NCT04365452

The Invia Motion at Cesarean Study

To assess patient centered outcomes of the Medela INVIA Motion prophylactic NPWT system at cesarean delivery.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

Female

Study type

Interventional

Phase

Phase 4

Primary location

Indiana University

Indianapolis, Indiana, 46202, United States

About this study

This study will be a two center case series of women undergoing caesarean delivery conducted at two medical centers in Indianapolis, Indiana.

All patients meeting inclusion criteria will be included. All enrolled patients will receive the Medela INVIA Motion prophylactic NPWT device.

Visit A: Interventional Procedure All enrolled patients will receive the Medela INVIA Motion device placed by the patient's surgeon after the skin is closed with subcuticular suture or staples. Research staff and clinicians (labor & delivery and postpartum nurses, OR technicians, physicians, etc.) involved in the study will receive formal training on how to place and remove the prophylactic NPWT device.

Visit B: Post Procedure until Discharge Patients will be monitored daily while in the hospital by clinical staff and/or research staff for complications.

The negative pressure wound therapy dressing will be removed on the day of discharge. If the patient remains hospitalized for more than 7 days, the dressing will be removed on postoperative day 7.

Replacement of any dressing that is saturated. If a patient develops infection with the NPWT device in place the device will be removed and the patient given standard SSI therapy as outlined below.

Patients will be educated about the signs and symptoms of infection and other study outcomes and encouraged to call their provider if these should arise.

Research staff document inpatient course regarding SSI. Management of surgical site infections will follow the Practice Guidelines of the Infectious Diseases Society of America.

Visit C: Postpartum Follow Up

We will use active surveillance by research staff to ascertain surgical site infections:

Research staff will follow-up with the research participant at time of discharge or within 48 hours post discharge (postpartum day 1-9) to assess for adverse events, assess the participant's pain, obtain their satisfaction with their dressing and aesthetic appearance of the incision.

Research staff will call subjects on approximately postoperative day 30 (±2 days). They will ask the patient standardized questions regarding wound complications, patient satisfaction, pain and aesthetic appearance. If the patient reports a hospital, clinic, or ER visit not associated with the study centers, the staff will obtain the name of the medical facility and request the records.

The EQ-5D-3L quality of life questionnaire will be administered at the 30-day call.

Medical records from postpartum clinic visits as well as records of unscheduled visits (to any hospital clinic or ER) will be sought to ascertain study outcomes.

At the time of the subject's standard of care postpartum appointment about 4-6 weeks after inpatient hospital discharge research staff will collect information on outcomes, pain and patient satisfaction. If the patient does not attend the clinical postpartum visit, the study staff will contact the subject by phone to collect the data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Scheduled/non-labor or unscheduled/labor cesarean delivery
  • Gestational age greater than or equal to 23 weeks

Exclusion criteria

  • Unwilling or unable to provide consent
  • Non-availability for postoperative follow-up
  • Contraindication to NPWT

Treatment and study plan

Invia Motion

Device

Invia Motion NPWT system at cesarean delivery

Primary outcomes

  1. Pain Scores: Discharge Time Frame

    Time frame: At post-operative day 3 (+/- 1 days)

    Pain scores (pain score on scale of 0 - 10); 0 represents no pain, 10 represents highest pain

  2. Pain Scores: Scores Postpartum Day 30

    Time frame: At postoperative day 30 (+/- 2 days)

    Pain scores (pain score on scale of 0 - 10); 0 represents no pain, 10 represents highest pain

  3. Patient Satisfaction: Scores Discharge Time Frame

    Time frame: At postoperative day 3 (+/- 1 days)

    Patient satisfaction scores (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

  4. Patient Satisfaction: Scores Postpartum Day 30

    Time frame: At postoperative day 30 (+/- 2 days)

    Patient satisfaction scores (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

  5. Patient Satisfaction With Aesthetic Appearance: Scale

    Time frame: At postoperative day 30 (+/- 2 days)

    Patient satisfaction with aesthetic appearance (satisfaction score on scale of 0 - 10); 0 represents no satisfaction, 10 represents highest satisfaction

Secondary outcomes

  1. Wound Infection; Proportion of Incidence

    Time frame: 4-6 Weeks Postpartum

    Composite wound complication; wound infection as diagnosed by treating clinician

  2. Wound Separation; Proportion of Incidence

    Time frame: 4-6 Weeks Postpartum

    Composite wound complication; wound separation as diagnosed by treating clinician

  3. Seroma; Proportion of Incidence

    Time frame: 4-6 Weeks Postpartum

    Composite wound complication; seroma as diagnosed by treating clinician

  4. Antibiotics Prescribed for Presumed SSI; Proportion of Incidence

    Time frame: 4-6 Weeks Postpartum

    Composite wound complication; antibiotics prescribed by treating clinician for wound-related infection

  5. Skin Blistering; Safety Outcomes

    Time frame: 4-6 Weeks Postpartum

    Safety outcome; proportion of incidence of skin blistering around surgical wound

  6. Allergic Reaction; Safety Outcomes

    Time frame: 4-6 Weeks Postpartum

    Safety outcome; proportion of allergic reaction to wound dressing

  7. Wound Bleeding; Safety Outcomes

    Time frame: 4-6 Weeks Postpartum

    Safety outcome; proportion of wound bleeding

Sponsors and collaborators

Lead sponsor

Indiana University

Other

Collaborators

  • Medela AG

Registry information

Official study title

Medela INVIA Motion NPWT System for Prophylactic Use on Surgical Incision After Cesarean Delivery

Important dates

Study start
2020
Primary completion
2020
Study completion
2020
First posted
Apr 28, 2020
Registry last updated
May 11, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.